AN INTERVENTIONAL, PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE DOSES OF ITRACONAZOLE ON THE PHARMACOKINETICS OF SINGLE DOSE ARV-471 IN THE FED CONDITION IN HEALTHY ADULT MALES, AND FEMALES OF NONCHILDBEARING POTENTIAL
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Vepdegestrant (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 29 Mar 2024 Results assessing the impact of itraconazole on the PK of vepdegestrant in healthy adult participants presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 01 Jun 2023 Status changed from recruiting to completed.
- 01 Mar 2023 Planned End Date changed from 14 Apr 2023 to 22 May 2023.